Loading...
Autoimmune Hemolytic Anemia as a Complication of Nivolumab Therapy
Recently, immunotherapeutic drugs, including PD-1 inhibitors (nivolumab, pembrolizumab), PD-L1 inhibitors (atezolizumab, avelumab), and CTLA4 inhibitors (ipiliumumab), have emerged as important additions to the armamentarium against certain malignancies and have been incorporated into therapeutic pr...
Na minha lista:
| Udgivet i: | Case Rep Oncol |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
S. Karger AG
2016
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5126613/ https://ncbi.nlm.nih.gov/pubmed/27920704 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000452296 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|